ELMO2抗体;ELMO2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse brain tissue, Human cerebella tissue lysates, Primary antibody: P13311(ELMO2 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P13311(ELMO2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13311(ELMO2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The ELMO2 (Engulfment and Cell Motility protein 2) antibody is a tool used to study the ELMO2 protein, a key regulator of cytoskeletal dynamics and cell migration. ELMO2 belongs to the ELMO family, which interacts with Dock180-family proteins to form complexes that activate Rac1 GTPase, a critical mediator of cell motility, phagocytosis, and tissue development. ELMO2 is implicated in processes such as neuronal development, immune cell trafficking, and cancer metastasis by promoting Rac1-dependent signaling pathways.

Research on ELMO2 antibodies focuses on detecting protein expression, localization, and functional roles in disease models. ELMO2 is overexpressed in certain cancers, correlating with invasive phenotypes and poor prognosis. Its involvement in receptor tyrosine kinase (RTK) pathways, including EGFR and MET, highlights its role in oncogenic signaling. Antibodies against ELMO2 enable studies on its interaction networks, post-translational modifications, and therapeutic targeting.

ELMO2 antibodies are also used to explore developmental biology, as ELMO2 deficiency in model organisms disrupts cell migration during embryogenesis. These antibodies are typically validated for specificity in applications like Western blotting, immunofluorescence, and immunohistochemistry. Understanding ELMO2's role in health and disease continues to advance insights into cell motility mechanisms and potential anti-metastatic strategies.